Evidence map›Paper›PMID 29843548›Full record

ReviewInternational review of psychiatry (Abingdon, England)2018

Cannabis regulatory science: risk-benefit considerations for mental disorders.

Jacob T Borodovsky, Alan J Budney

Abstract readReview
In one paragraph

Review in International review of psychiatry (Abingdon, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022
    Trial
  3. Artificial Intelligence Approximates Human Affect Ratings of Cannabis Images.medRxiv : the preprint server for health sciences · 2025
    Article
  4. Article
  5. Developing an online cannabis store paradigm for Cannabis Regulatory Science.medRxiv : the preprint server for health sciences · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. 3-Year Follow-up of Lower Risk Cannabis Use Patterns: Evidence from a Longitudinal Survey.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2022
    Article
  13. Article
  14. Article
  15. The importance of psychology for shaping legal cannabis regulation.Experimental and clinical psychopharmacology · 2021
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jacob T Borodovskya Center for Technology and Behavioral Health , Dartmouth Geisel School of Medicine , Lebanon , NH , USA.ORCID 0000-0001-7112-5677
Alan J Budneya Center for Technology and Behavioral Health , Dartmouth Geisel School of Medicine , Lebanon , NH , USA.

Funding

Treatment Development & Evaluation CoreP30DA029926 · NIDA · DARTMOUTH COLLEGE · PI Lisa A. Marsch · 2011 to 2026
$21.5M
Training in the Science of Co-Occurring DisordersT32DA037202 · NIDA · DARTMOUTH COLLEGE · PI Lisa A. Marsch · 2014 to 2026
$4.7M
Targeting tobacco cessation during treatment for cannabis use disordersR01DA032243 · NIDA · DARTMOUTH COLLEGE · PI BUDNEY, ALAN JEFFREY · 2012 to 2015
$1.7M
NIDA NIH HHS P30 DA029926NIDA NIH HHS R01 DA032243NIDA NIH HHS T32 DA037202
6 · The paper itself

Abstract

The evolving legal cannabis landscape in the US continues to present novel regulatory challenges that necessitate the development of a Cannabis Regulatory Science. Two specific issues of concern within Cannabis Regulatory Science are (1) the impact that cannabis use has on the incidence, prevalence, and severity of mental disorders, and (2) how cannabis laws and regulations modify this impact. This paper first provides several conceptual points that are useful for evaluating the relationship between cannabis use and mental disorders. Second, it selectively reviews and comments on data relevant to the relationship between cannabis use and depression, several forms of anxiety, post-traumatic stress disorder, schizophrenia, and bipolar disorder. Next, regulatory and public health parallels between the nascent cannabis industry and the pharmaceutical, tobacco, and alcohol industries are discussed. The focus is on specific types of industry practices that may harm those with or at risk for mental disorders. Recommendations are then offered for legal cannabis regulations that could mitigate this harm. Last, future research goals are discussed for building the field of Cannabis Regulatory Science and addressing the potential negative impact of cannabis on those with mental disorders.

Indexed as

Drug and Narcotic ControlRisk AssessmentHumansMedical MarijuanaMental DisordersMedical MarijuanaCannabislegalizationmarijuanamental disorderspsychiatricregulatory science

Identifiers

PMID29843548
PMCPMC6123285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.